Publications by authors named "M C Rinon"

Autologous hematopoietic stem cell transplantation (autoHSCT) is a standard of care for transplant-eligible patients with multiple myeloma (MM). Among factors that influence outcome after autoHSCT, it has been suggested that the number of natural killer (NK) cells plays an important role. However, the impact that different NK cell subsets and their phenotype could have in disease progression after autoHSCT are less clear.

View Article and Find Full Text PDF
Article Synopsis
  • Mature B-cell non-Hodgkin lymphoma (B-NHL) is a diverse group of cancers that vary in aggressiveness, with many patients experiencing relapse despite improved chemo-immunotherapy outcomes.
  • The sialomucin Podocalyxin (PODXL) is overexpressed in various tumors and is linked to cancer aggressiveness, but its specific role in hematological cancers like B-NHL has not been fully explored.
  • Recent research suggests that PODXL may influence B-NHL cell growth, survival, migration, drug resistance, and changes in metabolism, making it a potential target for new prognostic markers and therapies.
View Article and Find Full Text PDF

Podocalyxin (PCLP1) is a CD34-related sialomucin expressed by some normal cells and a variety of malignant tumors, including leukemia, and associated with the most aggressive cancers and poor clinical outcome. PCLP1 increases breast tumor growth, migration and invasion; however, its role in hematologic malignancies still remains undetermined. The purpose of this study was to investigate the expression and function of PCLP1 in mature B-cell lymphoma cells.

View Article and Find Full Text PDF

Autoimmune lymphoproliferative syndrome (ALPS) is a primary immunodeficiency caused by impaired Fas/FasL-mediated apoptosis of lymphocytes and is characterized by chronic nonmalignant or benign lymphoproliferation, autoimmune manifestations and expansion of double negative (DN) T-cells (TCRαβ+CD4-CD8-). Most cases of ALPS are associated with germline (ALPS-FAS) or somatic (ALPS-sFAS) heterozygous FAS mutations or a combination of both. Here we report three unrelated patients with ALPS-sFAS.

View Article and Find Full Text PDF